April 11, 2022 by Chain Drug Review
CVS, David Denton, Pizer
Leading Headlines, Supplier News
NEW YORK — Pfizer announced Monday that former CVS executive David Denton will join the company as chief financial officer (CFO) and executive vice president effective May 2. Denton will be a member of Pfizer’s Executive Leadership Team reporting to chairman and chief executive officer, Albert Bourla. He joins Pfizer from Lowe’s Companies where he
June 6, 2018 by Chain Drug Review
Aetna, CVS Health, CVS Health-Aetna, David Denton, Dr. Alan M. Lotvin, Dr. Harold Paz, Dr. Troyen Brennan, Jon Roberts, Jr., Karen Lynch, Larry Merlo, Lisa Bisaccia, Mark Bertolini, Meg McCarthy, Richard di Benedetto, Rick Jelinek, Shawn Guertin, Steven Kelmar, Thomas Moriarty, Thomas Sabatino
Business, Pharmacy, Retail News
WOONSOCKET, R.I. — CVS Health has announced the management team that, following the close of the Aetna acquisition, will lead the combined company into the future. Aetna will operate as a stand-alone business unit within the CVS Health enterprise following the close and will be led by members of its current management team. In addition,
February 8, 2018 by Chain Drug Review
CVS Health, CVS Pharmacy, David Denton, Larry Merlo, Tax Cuts & Jobs Act, TCJA
Business, Featured Articles, Leading Headlines, Retail News
WOONSOCKET, R.I. — Driven by growth in its pharmacy benefit management unit, and overcoming softness in its retail business, CVS Health posted increased sales and beat Wall Street’s earnings forecast for its 2017 fourth quarter and fiscal year. CVS said Thursday that for the fourth quarter ended Dec. 31, total revenue rose 5.3% to $48.39
January 15, 2018 by Scot Meyer and Chain Drug Review
CVS Health, CVS Health's 2018 earnings outlook, David Denton, Larry Merlo, Red Oak
2018, Issue 01-15-2018, Issues, News
WOONSOCKET, R.I. — CVS Health executives expressed confidence in the company’s growth strategy earlier this month, and also noted that the recently passed tax overhaul packaged should boost its cash flow by an estimated $1.2 billion. The remarks came in a conference call following an announcement of CVS Health’s 2018 earnings outlook. CVS Health said
January 5, 2018 by Scot Meyer and Chain Drug Review
CVS Health, CVS Pharmacy, David Denton, Larry Merlo, Red Oak
Business, Leading Headlines, Retail News
WOONSOCKET, R.I. — In an update for investors, CVS Health executives expressed confidence in its growth outlook and noted that the recently passed tax overhaul package should boost its cash flow by an estimated $1.2 billion. The remarks came yesterday in a conference call after the company’s announcement of its earnings expectations for 2018. CVS
February 6, 2017 by Geoff Walden and Chain Drug Review
CVS Health, David Denton, Edith Ramirez, Federal Trade Commission, Fred's, Maureen Ohlhausen, Rite Aid, Stefano Pessina, Terrell McSweeny, Walgreens Boots Alliance, Walgreens-Rite Aid merger
2017, Issue 02-06-2017, Issues, News
WASHINGTON — The acquisition of Rite Aid Corp. by Walgreens Boots Alliance (WBA) Inc. remained unconsummated after WBA’s plan to divest 865 stores failed to erase antitrust regulators’ competitive concerns. When the Friday, January 27, deadline for completing the Walgreens-Rite Aid merger deal arrived, the Federal Trade Commission still hadn’t cleared the transaction, despite the
January 4, 2016 by Geoff Walden and Chain Drug Review
Analyst Day, Cardinal Health, CVS Health, David Denton, Larry Merlo, Omnicare, Red Oak Sourcing, Target Corp.
2016, Business, Issue 01-04-2016, Issues, News
NEW YORK — CVS Health has raised the midpoint of its earnings outlook for 2016 and reiterated its five-year steady state targets. The company now expects next year’s adjusted earnings per share to range from $5.73 to $5.88, reflecting solid year-over-year growth of 11.25% to 14.25%. The bottom end of the range was increased by
December 3, 2015 by Chain Drug Review
Brian Cornell, CVS Health, David Denton, food/drug retailing, Institutional Investor, Larry Merlo, Target Corp.
CDR Blog
Larry Merlo, president and chief executive officer of CVS Health, was named the No. 1 CEO in the food/drug retailing sector by Institutional Investor magazine. Merlo was part of the financial publication’s “2016 All-America Executive Team,” in which more than 2,000 portfolio managers and analysts were asked to name the best CEOs, CFOs and investor